Charles River provides financial guidance for 2012

Thursday, December 15, 2011 02:59 PM

Charles River Laboratories International has provided guidance for 2012 and updated guidance for 2011. James C. Foster, Chairman, president and chief executive officer, said, “We made significant progress in 2011 on our four key initiatives, which include operating margin expansion, improved free cash flow, disciplined investment in existing growth businesses, and returning value to shareholders. In 2012, we will maintain our focus on these initiatives and on stimulating sales growth.”

“Our large biopharmaceutical clients are fundamentally rethinking their research processes; eliminating non-viable molecules earlier and focusing only on the most promising molecules. To further improve the efficiency and cost effectiveness of their research, they are increasingly choosing to outsource, particularly in the area of discovery services. Because of our expertise in in vivo biology, this is a significant opportunity for us, one on which we intend to capitalize," Foster added.

“We believe market conditions have stabilized, and visibility is improving. As a result, we view 2012 as a more stable year in which sales growth begins to strengthen in a range of 1% to 3% on a constant currency basis, and non-GAAP earnings per share increase between 7% and 11%, or in a range of $2.60 to $2.70," said Foster.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs